China Human Diploid Cell Based Hepatitis A Vaccine Product Manufacturer, Supplier, Factory

AIM Action Biopharmaceutical Co., Ltd. provides Human Diploid Cell Based Hepatitis A Vaccine Product for organizations seeking a stable vaccine supply option from an experienced biopharmaceutical manufacturer. The product is based on hepatitis A virus cultured in KMB17 human diploid cells, followed by virus purification and formaldehyde inactivation to prepare the final vaccine product. This production approach helps maintain antigen characteristics while removing the replication ability of the virus, supporting preventive immunization against hepatitis A.

Product Overview

Hepatitis A remains an important infectious disease that requires effective prevention strategies, especially in regions where vaccination programs are an essential part of public health management. AIM Action's Human Diploid Cell Based Hepatitis A Vaccine Product is designed for active immunization against hepatitis A virus infection by stimulating the body to develop protective immunity after vaccination.

The vaccine uses the hepatitis A virus Lv-8 strain as the production strain and KMB17 human diploid cell line as the culture substrate. After virus cultivation and harvesting, the viral suspension undergoes ultrafiltration, concentration, purification by chromatography, and inactivation treatment to produce the vaccine ingredient.

Compared with vaccine production methods based on animal-derived cell substrates, human diploid cell technology provides a well-established production platform with long-term application experience. AIM Action applies this technology to develop hepatitis A vaccine products suitable for pediatric and adult immunization needs.

Structure of hepatitis A virus

Cell Technology

The selection of a suitable cell substrate is a key factor in vaccine manufacturing. The production process of this vaccine uses KMB17 human diploid cell line, which was independently established by the Kunming Institute in 1974 and has been validated over a long period.

The use of human diploid cells allows manufacturers to establish a controlled and consistent production process. For vaccine procurement organizations, understanding the production platform helps evaluate product quality, manufacturing reliability, and long-term supply capability.

The hepatitis A virus used in production is the Lv-8 strain. This strain was isolated and screened by the Kunming Institute during the 1988 Shanghai Hepatitis A outbreak from a typical hepatitis A patient in Lüsi Town, Jiangsu Province. According to AIM Action's published information, this strain features a short replication cycle, high virus yield, stable characteristics, and good immunogenicity.

Manufacturing Process

The manufacturing process focuses on maintaining product consistency through multiple preparation steps. The main process includes:

1. Virus cultivation using the KMB17 human diploid cell substrate.

2. Harvesting and preparation of the viral suspension.

3. Ultrafiltration, concentration, and purification through chromatography.

4. Formaldehyde inactivation to eliminate viral replication ability while retaining antigen properties.

This controlled process supports the production of an inactivated vaccine that can be used as part of hepatitis A prevention programs.

Immunization Use

Different age groups require different dosage considerations during vaccination. AIM Action provides both pediatric and adult dosage specifications to meet different immunization requirements.

For children aged 1-15 years old (including 15 years old), the pediatric dosage is applied. For individuals over 15 years old, the adult dosage is used according to the product information.

The vaccination schedule includes a primary immunization dose followed by a booster dose after a 6-month interval. This two-dose approach helps recipients develop and maintain immune protection against hepatitis A virus.

Dosage Information

Quality Assurance

For vaccine procurement, quality consistency and manufacturing capability are important considerations. AIM Action Biopharmaceutical Co., Ltd. is part of AIM Vaccine and focuses on vaccine research, development, and manufacturing. The company has established vaccine production capabilities and commercialized multiple vaccine products.

AIM Action completed the construction of its inactivated hepatitis A vaccine production line, passed national GMP certification, and obtained relevant approvals for inactivated hepatitis A vaccine production. The company continues to improve vaccine manufacturing and quality management systems to support public health needs.

Why Choose AIM Action

Organizations selecting a vaccine supplier usually consider product technology, manufacturing experience, and supply reliability. AIM Action provides:

1. Human diploid cell-based production technology using KMB17 cell substrate.

2. Established hepatitis A vaccine manufacturing experience and production capability.

3. Vaccine products developed according to pharmaceutical manufacturing quality management requirements.

4. Support for different immunization requirements through pediatric and adult specifications.

Application Areas

Hepatitis A vaccination plays an important role in reducing the risk of hepatitis A virus transmission. The Human Diploid Cell Based Hepatitis A Vaccine Product can be considered for use in routine immunization programs, disease prevention initiatives, and healthcare vaccination services where hepatitis A prevention is required.

Vaccination organizations, medical institutions, and public health-related programs usually need products with stable manufacturing processes and clear technical information. AIM Action provides product documentation and specifications to support professional evaluation before procurement and application.

Suitable Application Scenarios

The vaccine may be applied in different immunization settings, including:

1. Routine childhood vaccination programs that require hepatitis A prevention for eligible children.

2. Adult vaccination services where hepatitis A immunization is recommended according to healthcare requirements.

3. Public health prevention programs designed to improve population protection against hepatitis A infection.

4. Medical and healthcare organizations requiring an approved hepatitis A vaccine supply option.

A complete vaccination strategy requires not only vaccine availability but also proper administration, storage conditions, and professional medical guidance. Users should follow applicable vaccination guidelines and healthcare instructions during application.

Immune Response

The effectiveness of a vaccine is closely related to its ability to stimulate the immune system and generate protective antibodies. According to AIM Action's published product information, the inactivated hepatitis A vaccine has a good immune effect in both adults and children.

Clinical evaluation information shows that the antibody conversion rate is similar to imported inactivated hepatitis A vaccines, while the geometric mean titer GMT (mIU/mL) of antibodies is better than imported hepatitis A vaccines.

Through inactivation technology, the vaccine retains important antigen characteristics while preventing viral replication. This allows the immune system to recognize hepatitis A virus-related antigens and establish immune memory after vaccination.

Technical Details

Understanding technical specifications helps healthcare organizations and procurement teams evaluate whether a vaccine product matches their application requirements. AIM Action provides clear dosage information and production background for professional product assessment.

Supplier Capability

Choosing a vaccine supplier requires consideration beyond the product itself. Procurement organizations need to evaluate manufacturing experience, regulatory background, and long-term cooperation capability.

AIM Honesty Biopharmaceutical Co., Ltd. focuses on vaccine research, development, manufacturing, and commercialization. As part of AIM Vaccine, the company has developed vaccine products and established professional production capabilities to support domestic and international healthcare needs.

The company participates in industry exhibitions and maintains communication with partners in the pharmaceutical field. These activities help AIM Action understand changing market requirements and improve cooperation efficiency with global customers.

Cooperation Support

AIM Action provides product information and technical communication support for customers evaluating vaccine products. During procurement discussions, customers can confirm product specifications, application requirements, and cooperation details with the professional team.

For healthcare organizations and distributors, clear communication before cooperation helps reduce uncertainty during product selection and supply planning.

Product Selection Guide

Selecting a hepatitis A vaccine requires attention to several important factors, including target population, dosage requirements, production technology, and supplier qualification. Different vaccination programs may have different requirements depending on local regulations and healthcare policies.

When evaluating a suitable vaccine product, customers can consider:

1. Target vaccination group: Confirm whether the product specification matches pediatric or adult immunization requirements.

2. Production technology: Review the cell substrate, virus strain, and manufacturing process information.

3. Quality documentation: Confirm available technical documents and product approval information.

4. Supply cooperation: Evaluate communication efficiency and supplier support capability.

AIM Action's Human Diploid Cell Based Hepatitis A Vaccine Product combines human diploid cell technology with an established hepatitis A vaccine manufacturing process, providing healthcare partners with a professional option for hepatitis A prevention programs.

Frequently Asked Questions

Q: What type of hepatitis A vaccine does AIM Action provide?

A: AIM Action provides an inactivated hepatitis A vaccine produced using the human diploid cell culture method. The vaccine uses the Lv-8 strain of hepatitis A virus and the KMB17 human diploid cell line as the production substrate.

Q: What is the difference between pediatric and adult dosage?

A: The pediatric dosage is 0.5ml per dose and contains 320 EU of hepatitis A virus antigen. It is used for individuals aged 1-15 years old. The adult dosage is 1.0ml per dose and contains 640 EU of hepatitis A virus antigen for individuals over 15 years old.

Q: How is the vaccine administered?

A: The vaccine should be shaken well before use and administered through intramuscular injection at the deltoid muscle attachment site on the outer side of the upper arm. Vaccination should follow professional medical guidance and applicable immunization requirements.

Q: Why is the KMB17 human diploid cell line used in production?

A: KMB17 is a human diploid cell line independently established by the Kunming Institute in 1974. According to AIM Action's published information, this cell line has been validated over a long period and provides a controlled substrate for vaccine production.

Q: What information should buyers confirm before purchasing?

A: Buyers should review product specifications, dosage requirements, technical documents, approval information, and supplier capabilities. Communication with the manufacturer can help confirm whether the product meets specific application requirements.

Q: Can this vaccine be used for both children and adults?

A: Yes. AIM Action provides different dosage specifications for children and adults. The appropriate dosage should be selected according to the recipient's age and professional vaccination guidance.

Summary

AIM Action's Human Diploid Cell Based Hepatitis A Vaccine Product is developed using human diploid cell technology and an established hepatitis A vaccine manufacturing process. Based on the Lv-8 strain and KMB17 human diploid cell substrate, the product provides a vaccine option for hepatitis A prevention among different age groups.

With pharmaceutical manufacturing experience, product approval background, and professional technical support, AIM Honesty Biopharmaceutical Co., Ltd. works with healthcare partners seeking reliable hepatitis A vaccine solutions. Customers can contact AIM Action for further product information and cooperation discussions.